Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival.

Autor:	Gomes RV; - Faculty of Medicine, Surgery Department, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil., Rodrigues MÂ; - Institute of Biological Sciences, General Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil., Rodrigues JBSR; - Faculty of Medicine, Surgery Department, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil., Vidigal PT; - Faculty of Medicine, Pathological Anatomy and Legal Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil., Damasceno KA; - Institute of Biological Sciences, General Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil., Lima HA; - Faculty of Medicine, Surgery Department, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil., Gomes DA; - Institute of Biological Sciences, Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil., Machado CJ; - Faculty of Medicine, Preventive and Social Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil., Resende V; - Faculty of Medicine, Surgery Department, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Jazyk:	English; Portuguese
Zdroj:	Revista do Colegio Brasileiro de Cirurgioes [Rev Col Bras Cir] 2018 Jul 10; Vol. 45 (3), pp. e1826. Date of Electronic Publication: 2018 Jul 10.
DOI:	10.1590/0100-6991e-20181826
Abstrakt:	Objective: to evaluate the expression of the epithelial growth factor receptor (EGFR) by immunohistochemistry, and to verify its association with prognostic factors and survival of patients operated by cholangiocarcinoma. Methods: we verified the immunohistochemical expression of EGFR in 35 surgical specimens of cholangiocarcinoma (CCA). We obtained survival curves with the Kaplan-Meier method. Results: we found significant EGFR expression in ten (28.6%) of the 35 CCAs, eight with score 3 and two with score 2. Advanced stages (III and IV) presented higher EGFR expression (p=0.07). The clinical characteristics that were most associated with positive EGFR expression were female gender (p=0.06) and absence of comorbidities (p=0.06). Overall survival at 12, 24, 36 and 48 months was 100%, 82.5%, 59% and 44.2%, respectively. The survival of EGFR positive patients at 12, 24, 36 and 48 months was 100%, 75%, 50% and 0%, whereas for negative EGFR patients it was 100%, 87.5%, 65.6% and 65.6%, respectively. Conclusion: EGFR expression occurred in 28.6% of the cases studied and was associated with lower survival.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu